LumaCina, the pharmaceutical supplier and marketing division of Bridgewest Perth Pharma, has announced new production of oral morphine to meet critical drug shortage in New Zealand.

The shortfall of oral morphine has become increasingly concerning in New Zealand, adversely affecting patients who rely on this medication to manage pain effectively. Recognising the gravity of the situation, LumaCina has been actively working in partnership with Pharmac, New Zealand's government agency responsible for pharmaceutical funding and access, to bridge the supply gap. LumaCina has made substantial investments to expand capabilities for steady supply of Oral Morphine.

Cyrus K. Mirsaidi, Global CEO for LumaCina and Bridgewest Perth Pharma said, "Through our collaboration with Pharmac, we are leveraging our collective expertise and resources to make a meaningful difference in the lives of patients across New Zealand."

Last year, Bridgewest Group made a key strategic move to broaden its life science ecosystem, expanding capabilities throughout research and development, manufacturing, and delivery. It acquired the Pfizer Perth cGMP sterile injectable manufacturing plant, and formed Bridgewest Perth Pharma, NovaCina CDMO division and LumaCina pharmaceutical supply division. LumaCina is a global supplier and marketer of sterile injectable pharmaceutical drugs located in Perth, Australia.